Atlas Trials

The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD

Clinical trial NCT05440422 · RECRUITING

Trial details

NCT number
NCT05440422
Sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Systemic Lupus ErythematosusCardiovascular DiseasePremature Atherosclerosis
Start date
2023-12-07
Primary completion
2027-08-01
Enrollment
45

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.